{"url_path":"/sec/eldn/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1404281/0001193125-26-221702-index.html","accession_number":"0001193125-26-221702","cik":"0001404281","ticker":"ELDN","issuer_name":"Eledon Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1404281/0001193125-26-221702-index.html","primary_entity_key":"0001404281","primary_entity_name":"Eledon Pharmaceuticals, Inc."},"word_count":2178,"has_tables":true,"body_markdown":"10-Q\n\n--12-31falseQ10001404281http://fasb.org/srt/2025#ChiefExecutiveOfficerMember10001404281us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001404281us-gaap:OperatingSegmentsMember2025-01-012025-03-310001404281us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001404281eldn:GuggenheimSecuritiesLlcMembereldn:EquityDistributionAgreementMembersrt:MaximumMember2024-09-202024-09-200001404281eldn:SeriesXNonVotingConvertiblePreferredStockMember2025-03-310001404281stpr:CA2022-01-012022-12-310001404281eldn:SeriesXAndSeriesX1NonVotingConvertiblePreferredStockMember2025-01-012025-03-310001404281us-gaap:CommonStockMembersrt:MinimumMembereldn:SeriesXNonVotingConvertiblePreferredStockMember2026-01-012026-03-310001404281eldn:CommonStockWarrantsMembereldn:TwoThousandAndTwentyFourUnderwrittenOfferingPre-FundedWarrantsMember2026-03-310001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2025-12-310001404281eldn:FiveHundredMillionAggregateNetSalesMembereldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2026-01-012026-03-310001404281eldn:UnderwrittenPublicOfferingMembereldn:UnderwritingAgreementMember2025-11-122025-11-120001404281eldn:PreFundedWarrantsMembersrt:MinimumMembereldn:TwoThousandAndTwentyFiveWarrantExchangeAgreementMembereldn:UnderwritingAgreementMember2025-12-302025-12-300001404281us-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-12-310001404281eldn:CommonStockWarrantsAndPreFundedWarrantsMember2026-03-310001404281us-gaap:CommonStockMember2025-03-310001404281eldn:TwoThousandTwentyLongTermIncentivePlanMember2024-07-102024-07-100001404281us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001404281us-gaap:CommonStockMember2025-12-3100014042812024-12-310001404281us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001404281us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100014042812026-03-310001404281us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2026-03-310001404281us-gaap:CommonStockMember2026-03-302026-03-300001404281us-gaap:USTreasurySecuritiesMember2025-12-310001404281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2025-12-310001404281us-gaap:AdditionalPaidInCapitalMember2025-03-310001404281us-gaap:CommonStockMember2026-03-3100014042812025-06-090001404281us-gaap:ConvertiblePreferredStockMember2025-12-310001404281stpr:MA2024-11-210001404281us-gaap:CommonStockMember2025-01-012025-03-310001404281us-gaap:CommonStockMembereldn:UnderwritingAgreementMembereldn:LeerinkPartnersLlcMember2025-11-120001404281us-gaap:CommonStockMembereldn:SeriesX1NonVotingConvertiblePreferredStockMembersrt:MaximumMember2025-01-012025-03-310001404281us-gaap:EmployeeStockOptionMembersrt:BoardOfDirectorsChairmanMembersrt:MinimumMember2026-01-012026-03-310001404281eldn:SecuritiesPurchaseAgreementMember2025-01-012025-12-310001404281eldn:AnelixisTherapeuticsIncorporationMember2020-09-142020-09-140001404281us-gaap:CommonStockMember2024-12-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2026-03-310001404281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2026-03-310001404281eldn:SeriesXAndX1NonVotingConvertiblePreferredStockMember2026-03-310001404281us-gaap:CommonStockMembersrt:MaximumMembereldn:UnderwritingAgreementMembereldn:LeerinkPartnersLlcMember2025-11-120001404281eldn:UnderwrittenPublicOfferingMembereldn:UnderwritingAgreementMember2025-11-120001404281us-gaap:ConvertiblePreferredStockMember2026-03-310001404281eldn:SeriesXNonVotingConvertiblePreferredStockMember2025-12-310001404281eldn:SecuritiesPurchaseAgreementInitialClosingMembereldn:AccreditedInvestorMemberus-gaap:PrivatePlacementMember2023-04-280001404281us-gaap:CommonStockMembereldn:SeriesX1NonVotingConvertiblePreferredStockMembersrt:MinimumMember2025-01-012025-03-310001404281eldn:CommonStockWarrantsMembereldn:CommonWarrantsMember2026-03-310001404281eldn:PreFundedWarrantsMember2025-01-012025-03-310001404281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2026-03-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2021-01-012021-12-310001404281us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001404281us-gaap:RetainedEarningsMember2025-01-012025-03-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2015-05-310001404281us-gaap:EmployeeStockOptionMembersrt:BoardOfDirectorsChairmanMember2026-01-012026-03-310001404281eldn:CommonStockWarrantsMember2025-12-310001404281eldn:PreFundedWarrantsMember2026-03-310001404281stpr:CA2022-08-122022-08-120001404281us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2025-12-310001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2024-12-310001404281us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001404281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2026-03-310001404281eldn:SeriesXAndSeriesX1NonVotingConvertiblePreferredStockMember2026-01-012026-03-310001404281us-gaap:RetainedEarningsMember2025-03-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2022-01-012022-12-310001404281eldn:UnderwritingAgreementMembereldn:LeerinkPartnersLlcMember2025-11-122025-11-120001404281eldn:CommonStockWarrantsMembereldn:TwoThousandAndTwentyThreeSecuritiesPurchaseAgreementCommonWarrantsMember2026-03-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMembereldn:OneBillionAggregateNetSalesMember2026-03-310001404281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2026-01-012026-03-3100014042812025-12-3100014042812026-05-070001404281eldn:CommonStockWarrantsMembereldn:TwoThousandAndTwentyFourSecuritiesPurchaseAgreementPre-FundedWarrantsMember2026-03-310001404281eldn:AnelixisTherapeuticsLlcAndOticPharmaLtdMember2026-01-012026-03-310001404281eldn:CommonStockWarrantsMembereldn:CommonWarrantsMember2025-12-310001404281us-gaap:AdditionalPaidInCapitalMember2025-12-310001404281srt:MinimumMember2026-01-012026-03-310001404281eldn:UnderwritingAgreementMembereldn:LeerinkPartnersLlcMember2025-11-132025-11-130001404281us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001404281eldn:LonzaSalesAGIncLicenseAgreementMember2026-01-012026-03-310001404281us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001404281eldn:TwoThousandFourteenStockIncentivePlanMember2026-03-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMembersrt:MaximumMember2026-03-310001404281us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001404281us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001404281eldn:CommonStockWarrantsMembereldn:TwoThousandAndTwentyFiveWarrantExchangeAgreementMember2026-03-310001404281us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001404281eldn:AccreditedInvestorMemberus-gaap:PrivatePlacementMember2023-04-280001404281us-gaap:CommonStockMembersrt:MaximumMembereldn:SeriesXNonVotingConvertiblePreferredStockMember2026-01-012026-03-310001404281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-12-310001404281us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001404281eldn:PreFundedWarrantsMembereldn:TwoThousandAndTwentyFiveWarrantExchangeAgreementMember2025-12-302025-12-300001404281us-gaap:RetainedEarningsMember2025-12-310001404281eldn:CommonAndPreferredWarrantsOutstandingMember2026-01-012026-03-310001404281us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001404281eldn:CommonStockWarrantsMember2026-03-310001404281eldn:PreFundedWarrantsMember2026-03-300001404281us-gaap:CommonStockMember2026-01-012026-03-310001404281us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001404281eldn:SecuritiesPurchaseAgreementMember2026-01-012026-03-310001404281eldn:CommonStockWarrantsMembereldn:TwoThousandAndTwentyThreeSecuritiesPurchaseAgreementPre-FundedWarrantsMember2026-03-310001404281us-gaap:USTreasurySecuritiesMember2026-03-310001404281us-gaap:RetainedEarningsMember2026-01-012026-03-310001404281us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001404281eldn:SeriesXAndSeriesX1NonVotingConvertiblePreferredStockMember2026-03-300001404281eldn:TwoThousandFourteenEmployeeStockPurchasePlanMember2026-03-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMembereldn:OneBillionAggregateNetSalesMember2026-01-012026-03-310001404281eldn:CommonStockWarrantsMembereldn:JanuaryTwoThousandAndTwentyOnePre-FundedWarrantsMember2026-03-310001404281us-gaap:AdditionalPaidInCapitalMember2026-03-310001404281us-gaap:FairValueMeasurementsRecurringMember2026-03-310001404281eldn:PreFundedWarrantsMembereldn:TwoThousandAndTwentyFiveWarrantExchangeAgreementMembersrt:MaximumMembereldn:UnderwritingAgreementMember2025-12-302025-12-300001404281eldn:SeriesXNonVotingConvertiblePreferredStockMember2026-03-310001404281eldn:OticPharmaIncMember2026-01-012026-03-310001404281eldn:LonzaSalesAGIncLicenseAgreementMember2025-01-012025-03-310001404281eldn:PreFundedWarrantsMembersrt:MaximumMembereldn:UnderwritingAgreementMember2025-11-122025-11-120001404281eldn:CommonStockWarrantsAndPreFundedWarrantsMember2026-01-012026-03-310001404281us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001404281eldn:PreFundedWarrantsMember2026-01-012026-03-310001404281eldn:AccreditedInvestorMemberus-gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementThirdClosingMember2023-04-280001404281us-gaap:EmployeeStockOptionMembersrt:BoardOfDirectorsChairmanMembersrt:MaximumMember2026-01-012026-03-3100014042812025-01-012025-03-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2026-01-012026-03-310001404281eldn:SecuritiesPurchaseAgreementMember2026-03-310001404281eldn:AccreditedInvestorMembereldn:SecuritiesPurchaseAgreementSecondClosingMemberus-gaap:PrivatePlacementMember2023-04-280001404281us-gaap:AdditionalPaidInCapitalMember2024-12-310001404281us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-3100014042812026-01-012026-03-310001404281us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001404281stpr:CA2024-04-192024-04-190001404281eldn:TwoThousandTwentyLongTermIncentivePlanMember2026-03-310001404281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001404281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001404281stpr:CA2024-04-190001404281us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001404281eldn:TwoThousandAndTwentyFiveWarrantExchangeAgreementMember2025-12-302025-12-300001404281us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001404281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-12-310001404281eldn:PreFundedWarrantsMembereldn:TwoThousandAndTwentyFiveWarrantExchangeAgreementMember2025-12-300001404281eldn:PreFundedWarrantsMembersrt:MaximumMembereldn:UnderwritingAgreementMembereldn:LeerinkPartnersLlcMember2025-11-122025-11-120001404281us-gaap:FairValueMeasurementsRecurringMember2025-12-310001404281us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001404281stpr:MA2024-09-042024-09-040001404281us-gaap:USGovernmentAgenciesDebtSecuritiesMember2026-03-310001404281eldn:CommonStockWarrantsMembereldn:PreFundedWarrantsMember2025-12-310001404281us-gaap:RetainedEarningsMember2026-03-310001404281eldn:PreFundedWarrantsMembersrt:MinimumMembereldn:UnderwritingAgreementMembereldn:LeerinkPartnersLlcMember2025-11-122025-11-120001404281eldn:FiveHundredMillionAggregateNetSalesMembereldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2026-03-310001404281us-gaap:OperatingSegmentsMember2026-01-012026-03-310001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2026-03-310001404281us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001404281eldn:SeriesXNonVotingConvertiblePreferredStockMember2024-12-310001404281stpr:MA2024-09-040001404281eldn:TwoThousandAndTwentyFiveUnderwrittenOfferingPre-FundedWarrantsMembereldn:CommonStockWarrantsMember2026-03-310001404281us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001404281eldn:CommonAndPreferredWarrantsOutstandingMember2025-01-012025-03-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2025-01-012025-03-3100014042812025-06-100001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2025-03-310001404281eldn:SecuritiesPurchaseAgreementMember2025-12-3100014042812025-03-310001404281eldn:CommonStockWarrantsMembereldn:PreFundedWarrantsMember2026-03-310001404281us-gaap:RetainedEarningsMember2024-12-31xbrli:pureutr:sqftiso4217:USDxbrli:sharesxbrli:shareseldn:Segmenteldn:Milestoneiso4217:USD\n\n[Table of Contents](#toc_page)\n\n \n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, DC 20549\n\n \n\nFORM 10-Q\n\n \n\n(Mark One)\n\n☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\nOR\n\n☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from to\n\nCommission File Number: 001-36620\n\n \n\nELEDON PHARMACEUTICALS, INC.\n\n(Exact Name of Registrant as Specified in its Charter)\n\n \n\n \n\nDelaware\n\n \n\n20-1000967\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n \n\n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n \n\n \n\n19800 MacArthur Blvd., Suite 250\n\nIrvine, California\n\n \n\n92612\n\n(Address of principal executive offices)\n\n \n\n(Zip Code)\n\n \n\n \n\n(949) 238-8090\n\nRegistrant’s telephone number, including area code\n\n \n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading\n\nSymbol(s)\n\n \n\nName of each exchange on which registered\n\nCommon Stock, $0.001 par value\n\n \n\nELDN\n\n \n\nNasdaq Capital Market\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\n \n\n \n\n \n\n \n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\n \n\n \n\n \n\nEmerging growth company\n\n☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No\n\nAs of May 7, 2026 there were 77,187,823 shares of the Registrant’s common stock outstanding.\n\n \n\n \n\n[Table of Contents](#toc_page)\n\n \n\nSpecial Note Regarding Forward-Looking Statements\n\nThis Quarterly Report on Form 10-Q contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. Any statements other than statements of historical or current fact in this Quarterly Report on Form 10-Q are forward looking statements. In some instances, you can identify forward-looking statements by the use of words such as “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “could,” “may,” “will,” and similar expressions, although not all forward-looking statements include such identifying words. Forward-looking statements include, but are not limited to statements regarding:\n\n•\nour product development plans, expectations for and the timing of commencement, enrollment, completion, data, and release of results of clinical trials for our product candidates;\n\n•\nour estimates regarding our liquidity, expenses, capital requirements and needs for additional financing;\n\n•\nour strategies with respect to our preclinical and clinical development programs, including our expectations regarding the production of clinical quantities of our product candidates;\n\n•\nour plans, strategy and timing to obtain and maintain regulatory approvals of our product candidates;\n\n•\nour expectations regarding competitive conditions for our product candidates; and\n\n•\nour expectations about our future financial performance or condition.\n\nAlthough we believe that we have a reasonable basis for each forward looking statement contained in this Quarterly Report on Form 10-Q, actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including the factors listed under “Risk Factor Summary” below. These risks and uncertainties, as well as other risks and uncertainties that could cause the Company’s actual results to differ significantly from the forward-looking statements contained herein, are described in greater detail in Part II, Item 1A. Risk Factors in this Quarterly Report on Form 10-Q.\n\nForward-looking statements contained in this Quarterly Report on Form 10-Q are based on our current beliefs, assumptions, expectations, estimates and projections, which may be impacted by known or unknown factors. Any forward-looking statements contained in this Quarterly Report on Form 10-Q speak only as of the date hereof and not as of any future date, and the Company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise. You are therefore cautioned not to place undue reliance on the forward-looking statements included in this Quarterly Report on Form 10-Q.\n\nThe market data and certain other statistical information used in this Quarterly Report on Form 10-Q are based on independent industry publications, governmental publications, reports by market research firms or other independent sources. Some data are also based on our good faith estimates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.\n\n2\n\n[Table of Contents](#toc_page)\n\n \n\nRISK FACTOR SUMMARY\n\nThe following summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in Part II, Item 1A. Risk Factors in this Quarterly Report on Form 10-Q. This summary should be read in conjunction with the Risk Factors section and should not be relied upon as an exhaustive summary of the material risks facing our business. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business.\n\n•\nOur short operating history and shifts in our business strategy may make it difficult to evaluate the success of our business to date and to assess our future viability.\n\n•\nWe have incurred significant operating losses since our inception and expect that we will continue to incur losses over the next several years and may never achieve or maintain profitability.\n\n•\nWe will require additional funding to be able to complete the development of our lead drug candidate. If we are unable to raise such capital, or if we are unable to do so on acceptable terms, we will be forced to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether.\n\n•\nFuture issuances of our common stock, including common stock that may be issuable pursuant to outstanding warrants or other convertible securities, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.\n\n•\nOur product candidates are in the early stages of clinical development and may not be successfully developed. If we are unable to successfully develop and commercialize these or any other product candidate, or if we experience significant delays in doing so, our business will be materially harmed.\n\n•\nPublic health crises, including pandemics or epidemics could adversely affect our business.\n\n•\nUnfavorable global economic conditions could have a material adverse effect on our business.\n\n•\nAdverse conditions in the financial markets, including bank failures, could adversely affect our liquidity and financial performance.\n\n•\nDrug development involves a lengthy and expensive process with an uncertain outcome, including failure to demonstrate safety and efficacy to the satisfaction of the U.S. Food and Drug Administration (“FDA”) or similar regulatory authorities outside the United States. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development, formulation and commercialization of our product candidates.\n\n•\nThe results of non-clinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, and there is a risk that additional non-clinical and/or clinical safety studies will be required by the FDA or similar regulatory authorities outside the United States or that subsequent studies will not match results seen in prior studies.\n\n•\nDelays or difficulties in the enrollment of patients in clinical trials could delay or prevent our receipt of necessary regulatory approvals and increase expenses for the development of our product candidates.\n\n•\nOur ability to conduct clinical trials in some jurisdictions outside of the United States may be adversely affected.\n\n•\nIf serious adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.\n\n•\nOur future success depends on our ability to retain executives and key employees and to attract, retain and motivate qualified personnel in the future.\n\n•\nIf we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, or the approvals may be for a narrow indication, we may not be able to commercialize our product candidates, and our ability to generate revenue may be materially impaired.\n\n•\nLegislation regulating the pharmaceutical and healthcare industries may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.\n\n•\nOur internal computer systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer security breaches, disruptions, or incidents, which could result in a material disruption\n\n3\n\n[Table of Contents](#toc_page)\n\n \n\nof our development programs or loss of data and have a material adverse effect on our reputation, business, financial condition or results of operations.\n\n•\nThe compromise of privacy, security, integrity or confidentiality of sensitive information related to our business or failure to comply with confidentiality and data privacy obligations could have a material adverse effect on our business.\n\n•\nEven if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success.\n\n•\nIf our current product candidates, or a future product candidate receives marketing approval and we, or others, later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the product could be compromised.\n\n•\nWe face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.\n\n•\nThe insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.\n\n•\nOur reliance on third parties for the manufacture of our product candidates for non-clinical and clinical trials, and for eventual commercialization, increases the risk that we will not have sufficient quantities of our product candidates or products at an acceptable cost and quality, which could delay, prevent or impair our development or commercialization efforts.\n\n•\nWe depend on contract research organizations (“CROs”) and other contracted third parties to perform non-clinical and clinical testing and certain other research and development activities. As a result, the outcomes of the activities performed by these organizations will be, to a certain extent, beyond our control.\n\n•\nIf we are unable to obtain and maintain intellectual property protection for our technology and products or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.\n\n•\nOur stock price could be volatile, and the market price of our common stock may drop unexpectedly.\n\n•\nIf we fail to maintain effective internal controls, we may conclude that our internal control over financial reporting is not effective, which could adversely affect our ability to report our results of operations and financial condition accurately and in a timely manner.\n\n•\nProvisions in our corporate charter and under Delaware law could make an acquisition of the Company more difficult and may prevent attempts by our stockholders to replace or remove our current management.\n\n \n\nWEBSITE REFERENCES\n\nIn this Quarterly Report on Form 10-Q, we make references to our website at www.eledon.com. References to our website through this Form 10-Q are provided for convenience only and the content on our website does not constitute a part of, and shall not be deemed incorporated by reference into, this Quarterly Report on Form 10-Q.\n\n4\n\n[Table of Contents](#toc_page)\n\n \n\nELEDON PHARMACEUTICALS, INC.\n\nFORM 10-Q\n\nFOR THE QUARTER ENDED MARCH 31, 2026\n\nTable of Contents\n\n \n\nPage\n\n \n\n \n\n \n\n \n\nPART I.\n\n[FINANCIAL INFORMATION](#part_i_financial_information)"}